Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest schizophrenia Stories

2013-10-24 08:36:01

MOUNTAIN VIEW, Calif. and BARCELONA, Spain, Oct. 24, 2013 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Grupo Ferrer Internacional, S.A. (Ferrer) today announced that ADASUVE(®) inhalation powder, pre-dispensed (Staccato(®) loxapine) is now available in Austria. Ferrer is Alexza's commercial partner for ADASUVE in the European Union (EU), Latin America, Russia and the CIS countries. Ferrer is commercializing ADASUVE in Austria through a distribution agreement...

2013-10-21 23:01:46

The Firm is investigating the alleged association between Risperdal and male breast growth, also known as gynecomastia. New York, New York (PRWEB) October 21, 2013 The nationwide law firm of Bernstein Liebhard LLP (http://www.consumerinjurylawyers.com) is investigating Risperdal lawsuits on behalf of young men and boys who developed a condition called gynecomastia, or male breast growth, allegedly due to their use of Risperdal. “We are interested in hearing from anyone who developed...

2013-10-17 08:28:56

-- PDE10 Target Engagement Continues to Increase with Well-Tolerated Doses - SEATTLE, Oct. 17, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. This latest clinical trial evaluated the extent to which OMS824, at a dose higher than previously reported, binds to PDE10, an enzyme expressed in the region of the brain that has been linked...

Schizophrenia Linked To Abnormal Brain Network
2013-10-16 16:23:29

Alan McStravick for redOrbit.com - Your Universe Online Individuals suffering with schizophrenia are subject to a whole host of disturbing, life-changing symptoms. They can range from disorganized thinking and an inability to plan for the future to full-on hallucinations and paranoid delusions. Through treatment with psychiatric therapy and medication can be effective for some, the psychiatric disease has largely remained a medical mystery. However, researchers at the RIKEN-MIT Center...

2013-10-08 23:32:49

Insights based on the Dimensional Systems Model are discussed in the Neuropsychotherapist magazine. “Speculation” is a regular column about the leading edge of research and theory, with a leaning toward the more speculative areas of thought. Greenville, South Carolina (PRWEB) October 08, 2013 Clinical psychologist Robert A. Moss, Ph.D., ABN, ABPP is the author of an article on the implications of the columnar brain code (Dimensional Systems Model) and its applied treatment approach...

2013-10-07 13:47:34

This press release is in support of a presentation by Professor Michael Berk on Monday Oct. 7 at the 26th ECNP Congress in Barcelona, Spain Improved understanding of the roles of inflammation and oxidative stress in psychiatric disorders has generated new leads in the search for novel therapies. One such investigative compound currently in clinical trials is an amino acid, N-Acetyl Cysteine (NAC), which appears to reduce the core symptoms of bipolar disorder, schizophrenia, depression,...

2013-09-30 08:28:47

-- Phase 2 Clinical Trial in Huntington's Disease Slated to Begin This Year -- SEATTLE, Sept. 30, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) announced that OMS824, its phosphodiesterase 10 (PDE10) inhibitor, has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of Huntington's disease. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including...

2013-09-26 08:28:21

MCO's Support for Generics May Limit Prescribing of Branded Therapies for Schizophrenia, According to a New Report from Decision Resources BURLINGTON, Mass., Sept. 26, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that branded therapies treating schizophrenia, bipolar disorder and depression may encounter reduced use on health insurance exchange plans that are set to launch in January...

2013-09-19 08:28:17

-- PDE10 Inhibitor Administered to Patients with Schizophrenia -- SEATTLE, Sept. 19, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ:OMER) today announced initiation of enrollment in a Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor. The trial will evaluate the compound's tolerability, safety, pharmacokinetics, potential interactions with concomitant antipsychotic medications, and a battery of cognitive tests in patients with stable...

2013-09-18 15:37:55

Schizophrenia is a potentially debilitating mental illness affecting a person's thought processes, perception, language and sense of oneself. Globally, 7 out of every 1000 are affected, accounting for 24 million patients. Significant risk factors for the illness in males is serious problems during birth or fetal hypoxia while increased cerebral ventricular size in both infancy and adulthood due to embryological defects can underlie the condition in other patients. However, it is a...